Concepedia

Detection of anti-infliximab antibodies is impacted by antibody titer, infliximab level and IgG4 antibodies: a systematic comparison of three different assays

Joana Afonso, Susana Lopes, Raquel Gonçalves, Paulo Caldeira, Paula Lago, Helena Tavares de Sousa, Jaime Ramos, Ana Rita Gonçalves, Paula Ministro, Isadora Rosa,

Therapeutic Advances in Gastroenterology · 2016 · 18 citations · 17 references

DOIFull text

Open access

Abstract

All three methodologies are equally suitable for measuring IFX levels. However, erroneous therapeutic decisions may occur when patients show double-negative (IFX-/ADAs-) or double-positive (IFX+/ADAs+) status, since agreement between assays is significantly lower in these circumstances.

References

17

The Measurement of Observer Agreement for Categorical Data

J. Richard Landis, Gary G. Koch · Biometrics · 1977 · 76.3K citations · Full text

, , +20

Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease

Filip Baert, Maja Noman, Séverine Vermeire et al. · New England Journal of Medicine · 2003 · 2K citations · Full text

Individualised therapy is more cost-effective than dose intensification in patients with Crohn’s disease who lose response to anti-TNF treatment: a randomised, controlled trial

Casper Steenholdt, Jørn Brynskov, Ole Østergaard Thomsen et al. · Gut · 2013 · 451 citations

Association Between Serum Concentration of Infliximab and Efficacy in Adult Patients With Ulcerative Colitis

Omoniyi J. Adedokun, William J. Sandborn, Brian G. Feagan et al. · Gastroenterology · 2014 · 328 citations · Full text

Levels of Drug and Antidrug Antibodies Are Associated With Outcome of Interventions After Loss of Response to Infliximab or Adalimumab

Henit Yanai, Lev Lichtenstein, Amit Assa et al. · Clinical Gastroenterology and Hepatology · 2014 · 306 citations

, , +6